do peptides help FAQ

Delay peptide therapy until the inflammatory phase peaks. Typically days 7–10 post-injury for acute tears. Administering growth-promoting peptides during active inflammation (days 1–5) can prolong the inflammatory cascade by signaling tissue repair before debris clearance is complete, which increases scar tissue formation. Wait until pain and swelling begin to stabilize, then initiate BPC-157 or TB-500 during the early proliferation window when fibroblast activity becomes the dominant healing driver.

You shouldn't expect one. Peptides help with energy through structural metabolic changes. Mitochondrial biogenesis, IGF-1 elevation, immune normalization. That take 2–6 weeks to manifest subjectively. The first noticeable changes are typically improved sleep quality and reduced next-day soreness, not immediate stamina increases. Growth hormone secretagogues need 10–14 days to elevate IGF-1 levels meaningfully, and mitochondrial adaptation follows 3–4 weeks later.

First, verify dosing frequency. Single daily administration raises acute GH but produces minimal IGF-1 change. You need 2–3 doses daily to sustain the signal long enough for hepatic IGF-1 synthesis to respond. Second, check meal timing. Dosing too close to carbohydrate intake negates the effect. Third, consider baseline: if your natural IGF-1 is already in the upper-normal range (>250ng/mL), peptides produce smaller relative increases because your pituitary capacity is near maximum.

Administer liposomal glutathione at 500–1000 mg daily in divided doses (morning and evening) to maintain elevated hepatic and plasma GSH levels throughout the day. Chronic low-level exposure to air pollutants, pesticide residues, or occupational chemicals creates sustained oxidative stress that depletes glutathione faster than dietary synthesis can replenish it. Exogenous supplementation shifts the balance back toward antioxidant capacity. Effectiveness depends on exposure intensity: heavy metal workers or individuals in high-pollution urban areas show measurable benefit; office workers with minimal exposure likely won't.

Non-response after 3 months of consistent peptide administration (verified serum IGF-1 increase <15%) indicates one of three issues: structural pituitary damage, incorrect dosing or reconstitution, or genuine resistance due to GHS-R1a downregulation. Baseline testing should have ruled out structural damage. If it didn't, an MRI pituitary protocol is warranted. If dosing and storage were correct (peptides stored at 2-8°C, reconstituted with bacteriostatic water, administered subcutaneously at appropriate intervals), the issue is likely receptor desensitization from prior chronic ghrelin receptor activation or genetic polymorphisms affecting receptor density. In research contexts, non-responders sometimes benefit from switching peptide classes. If a GHRP failed, try a GHRH analog, or vice versa. But if both fail, exogenous rhGH becomes the only viable option.

Thymic peptides offer prophylactic benefit by restoring cellular immunity that's been suppressed by chemotherapy, HIV, or immunosuppressive medications. Thymalin administered at 10 mg subcutaneously every 3–5 days for 2–4 weeks before anticipated immune challenge (surgery, chemotherapy cycle) increases CD3+ T-cell counts and normalises CD4:CD8 ratios. Clinical trials in oncology patients showed 40–60% reduction in opportunistic infection rates when thymic peptides were used prophylactically. This isn't immediate protection—start the protocol at least 7–10 days before the immune challenge occurs.

Focus on mitochondrial efficiency and metabolic preservation. MOTS-c and NAD+ precursor peptides target systems that begin declining in your 30s but haven't collapsed yet. Immune peptides are less urgent until thymic involution becomes clinically significant (usually post-50). Telomerase activation in your 40s is speculative. Most researchers recommend waiting until telomere shortening is measurable through SpectraCell or TeloYears testing.

Combining abstinence with glutathione (600 mg daily) and Thymalin (subcutaneous injection per research protocol) accelerates normalization of liver enzyme markers and oxidative stress biomarkers compared to abstinence alone. But the primary driver of hepatic recovery is removal of the alcohol itself. Alcohol metabolism generates acetaldehyde, a highly reactive toxin that depletes glutathione and damages mitochondria; peptides restore antioxidant defenses but cannot counteract ongoing toxic exposure. Recovery timelines: mild hepatic steatosis reverses in 2–4 weeks with abstinence alone; peptide support may shorten this to 10–14 days based on preclinical enzyme recovery data.

Yes, but wait 4–6 weeks post-injection before starting peptide protocols. Corticosteroids suppress collagen synthesis for several weeks after administration, and introducing a pro-anabolic peptide during this window creates conflicting tissue signals. Once the steroid clears, peptides help with plantar fasciitis by reactivating the fibroblast response the injection temporarily shut down. Case reports suggest combining BPC-157 with progressive loading exercises after the corticosteroid washout period produces better long-term outcomes than either intervention alone.

Selank's anxiolytic effects are dose-dependent but its sleep architecture benefits require cumulative BDNF modulation over 2–3 weeks. Missing 2–3 doses in a 20-day cycle delays peak effect but doesn't negate prior progress. Resume dosing at the next scheduled administration without doubling up. If you miss more than 5 consecutive days, restart the cycle from day 1. Partial BDNF modulation without completion produces inconsistent results. Selank does not cause withdrawal, so stopping mid-cycle carries no rebound risk.

No. Exogenous testosterone suppresses the HPG axis through negative feedback. Your hypothalamus senses elevated testosterone and stops releasing GnRH, which means no LH, which means your testes stop producing testosterone. Peptides that stimulate GnRH or LH can't override this feedback loop while you're administering exogenous testosterone. Some clinicians use human chorionic gonadotropin (hCG) alongside TRT to maintain testicular function. HCG mimics LH and can preserve some degree of intratesticular testosterone production. But that's not a peptide in the kisspeptin or gonadorelin category.

Yes, with caveats. Add GHK-Cu or Capixyl to your regimen only if you've plateaued on minoxidil after 12+ months. A 2007 UCSF trial found minoxidil plus GHK-Cu delivered 31% more regrowth than minoxidil alone. The peptide addresses inflammation minoxidil doesn't target. Apply peptide serum 30 minutes before or after minoxidil to avoid dilution.

No. Primary hypogonadism means your testes can't produce testosterone even when LH and FSH levels are elevated. The problem is testicular failure, not signaling failure. Stimulating upstream hormones with peptides won't help because the target organ (your testes) can't respond. Men with primary hypogonadism require testosterone replacement therapy; peptides that act on the HPG axis are indicated only for secondary hypogonadism, where the hypothalamus or pituitary is underperforming but the testes remain functional.

Not all CIRS cases respond to immune modulation alone. Roughly 30% of patients have concurrent genetic polymorphisms (MTHFR, COMT, GST variants) that impair detoxification pathways independent of immune function. No amount of Treg upregulation will clear mycotoxins if phase II liver conjugation is compromised. If TGF-β1, MMP-9, or C4a remain elevated after 8–12 weeks on a structured peptide protocol, the next step is functional genomics testing and targeted support for methylation or glutathione synthesis pathways. Peptides address immune dysregulation, not enzymatic bottlenecks.

Yes, but the combination is redundant and risks melatonin oversupply. Epithalon increases endogenous melatonin production, while exogenous melatonin supplements provide synthetic melatonin. Taking both simultaneously can produce excessive melatonin levels (>10 mg circulating), which paradoxically delays sleep onset and causes next-morning grogginess. If using epithalon, discontinue exogenous melatonin supplementation or reduce it to ≤1 mg. Monitor subjective sleep quality and adjust based on response. The goal is optimised melatonin rhythm, not maximal melatonin dose.

Switch to an intermittent dosing schedule or rotate peptides. Hexarelin and GHRP-6 are known to cause receptor desensitisation after 4–6 weeks of continuous use, reducing GH output by 40–60%. Ipamorelin and CJC-1295 show significantly less tachyphylaxis, but if reduced response is observed, a 5-days-on, 2-days-off protocol allows GHSR-1a receptors to resensitise. Alternatively, rotating between different GHS classes (GHRH analogs vs ghrelin mimetics) every 8–12 weeks prevents receptor downregulation without interrupting the study timeline. MK-677 is less prone to tachyphylaxis than injectable GHRPs but still benefits from periodic cycling.

Reassess the injury type and consider imaging. Peptides help with shoulder injury involving soft tissue damage but don't address structural issues requiring surgical repair. Full-thickness rotator cuff tears larger than 3 cm, displaced labral tears with mechanical catching, or grade III AC joint separations won't heal with peptide therapy alone regardless of protocol duration. If pain persists or function hasn't improved measurably by week 6, obtain MRI evaluation to rule out surgical indications. Peptides accelerate healing in repairable tissue. They don't replace anatomical reconstruction.

Do not use it. Cloudiness indicates bacterial contamination or peptide aggregation. Both render the compound inactive or unsafe. Lyophilised peptides should reconstitute into a clear, colourless solution. Discolouration (yellow, brown, pink) suggests oxidative degradation or impurity. Contact the supplier immediately. At Real Peptides, every batch undergoes sterility testing and HPLC verification before shipping. Contamination is rare with proper sourcing.

Most peptides don't have direct pharmacokinetic interactions with stimulants (amphetamines, methylphenidate) or cholinergics (donepezil, rivastigmine), but the combination can amplify side effects or mask underlying issues. Growth hormone secretagogues like MK 677 increase appetite and can cause insulin resistance. Combining with stimulants that suppress appetite creates conflicting metabolic signals. Cerebrolysin's neurotrophic effects are synergistic with acetylcholinesterase inhibitors in dementia treatment, but the combination requires medical supervision. If you're on prescription cognitive enhancers, peptide addition should be discussed with your prescribing physician. Not because of contraindication risk, but because outcome tracking becomes impossible without knowing which agent is driving observed changes.

No. Peptide-induced melanin persists as long as the melanin-containing keratinocytes remain in the epidermis. Most users maintain visible pigmentation for 2–4 weeks after the last dose, fading gradually as keratinocytes turn over and slough off. The fade rate matches natural skin cell turnover. Faster on the face (14–21 days) than the torso or limbs (28–35 days). You can extend the tan with maintenance dosing (0.25mg twice weekly), which keeps melanocyte activity elevated without continuous daily administration.